| 101 |
26106623 | Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D. | 2015 |
1 |
| 102 |
26132275 | Potentiation of Glibenclamide Hypoglycaemia in Mice by MK-467, a Peripherally Acting Alpha2-Adrenoceptor Antagonist. | 2015 Dec |
1 |
| 103 |
26142890 | Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis. | 2015 Sep |
1 |
| 104 |
26316711 | Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications. | 2015 |
1 |
| 105 |
26331221 | Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea. | 2015 Dec |
1 |
| 106 |
26445623 | What's next after metformin? focus on sulphonylurea: add-on or combination therapy. | 2015 Apr-Jun |
1 |
| 107 |
26548081 | Interaction of mouse intestinal P-glycoprotein with oral antidiabetic drugs and its inhibitors. | 2015 Sep |
1 |
| 108 |
26579078 | Metabolomic insights into the intricate gut microbial-host interaction in the development of obesity and type 2 diabetes. | 2015 |
1 |
| 109 |
26664768 | Hypoglycemia Secondary to Sulfonylurea Ingestion in a Patient with End Stage Renal Disease: Results from a 72-Hour Fast. | 2015 |
3 |
| 110 |
23959658 | Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy. | 2014 Jan |
1 |
| 111 |
24101534 | Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. | 2014 Feb |
1 |
| 112 |
24150606 | OATP1B3 is expressed in pancreatic β-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide. | 2014 Feb |
1 |
| 113 |
24329524 | Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes. | 2014 Apr |
1 |
| 114 |
24563333 | Sulfonylureas: a new look at old therapy. | 2014 Apr |
1 |
| 115 |
24876433 | Predictors of insulin initiation in metformin and sulfonylurea users in primary care practices: the role of kidney function. | 2014 Sep |
3 |
| 116 |
24931673 | Determination of personalized diabetes treatment plans using a two-delay model. | 2014 Oct 21 |
1 |
| 117 |
25213702 | High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). | 2014 Dec |
2 |
| 118 |
25238204 | Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. | 2014 Dec |
2 |
| 119 |
25311795 | Optical control of insulin release using a photoswitchable sulfonylurea. | 2014 Oct 14 |
2 |
| 120 |
25782302 | [Hypoglycemic activity of hypolipidemic preparations]. | 2014 |
1 |
| 121 |
27200691 | Factors Associated With Discontinuation of Sulfonylurea Therapy In Type 2 Diabetes Patients Who Initiate Insulin. | 2014 Nov |
1 |
| 122 |
27200692 | Impact of Hypoglycemia on Discontinuing or Down-Titrating Sulfonylurea Among Type 2 Diabetes Patients Without Insulin. | 2014 Nov |
1 |
| 123 |
23149657 | Short duration of diabetes and disuse of sulfonylurea have any association with insulin cessation of the patients with type 2 diabetes in a clinical setting in Japan (JDDM 30). | 2013 |
3 |
| 124 |
23350795 | Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. | 2013 Jul |
1 |
| 125 |
23372169 | Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. | 2013 Feb |
2 |
| 126 |
23434183 | Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report. | 2013 Apr |
1 |
| 127 |
23494446 | Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. | 2013 May |
1 |
| 128 |
23509454 | Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide. | 2013 |
1 |
| 129 |
23608551 | Continue with long term sulfonylureas in patients with mutations in the KCNJ11 gene when there is evidence of response even if insulin treatment is still required. | 2013 Jun |
1 |
| 130 |
23637538 | Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. | 2013 |
1 |
| 131 |
23797471 | Complementing insulin therapy to achieve glycemic control. | 2013 Jun |
1 |
| 132 |
23921548 | The TRPA1 channel and oral hypoglycemic agents: is there complicity in β-cell exhaustion? | 2013 Nov-Dec |
2 |
| 133 |
24150255 | Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. | 2013 Oct 22 |
2 |
| 134 |
24968533 | Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels. | 2013 Sep |
1 |
| 135 |
22118705 | Treating diabetes today: a matter of selectivity of sulphonylureas. | 2012 Jan |
1 |
| 136 |
22257418 | Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy. | 2012 Jun |
2 |
| 137 |
22471336 | Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease. | 2012 Apr 1 |
1 |
| 138 |
22533711 | ABCC8 polymorphisms are associated with triglyceride concentration in type 2 diabetics on sulfonylurea therapy. | 2012 Aug |
1 |
| 139 |
22563248 | Uncovering undetected hypoglycemic events. | 2012 |
2 |
| 140 |
22570146 | Hypoglycemia in hospitalized patients treated with sulfonylureas. | 2012 Jul |
1 |
| 141 |
22699113 | The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. | 2012 Sep-Oct |
1 |
| 142 |
22768894 | In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. | 2012 May 1 |
2 |
| 143 |
22978060 | Sulfonylurea-responsive neonatal diabetes mellitus diagnosed through molecular genetics in two children and in one adult after a long period of insulin treatment. | 2012 Apr |
1 |
| 144 |
23019799 | Glycemic control and weight changes in patients with type 2 diabetes intensified to three insulin regimens after therapeutic failure to exenatide. | 2012 Jul-Aug |
1 |
| 145 |
23028231 | Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. | 2012 |
2 |
| 146 |
23076984 | Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus. | 2012 Nov |
4 |
| 147 |
23078974 | New avenues for the pharmacological management of type 2 diabetes: an update. | 2012 Nov |
1 |
| 148 |
23148347 | Is thiazolidinediones use a factor in delaying the need for insulin therapy in type 2 patients with diabetes? A population-based cohort study. | 2012 |
2 |
| 149 |
23156508 | [Adverse effects of insulin secretagogues (sulfonylureas and glinides)]. | 2012 Aug |
1 |
| 150 |
21133673 | Exchange protein directly activated by cyclic AMP isoform 2 is not a direct target of sulfonylurea drugs. | 2011 Feb |
1 |